DDInter706 DDInter1763
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Exenatide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Digoxin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Exenatide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) SMARCD2
SMARCD2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Exenatide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) CDK19
CDK19 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dobutamine
Dobutamine {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Thrombocytopenia {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Exenatide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lovastatin
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Exenatide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Digoxin {u} (Compound) downregulates {v} (Gene) TCEA2
TCEA2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Exenatide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Etonogestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Exenatide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Temsirolimus (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Exenatide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates SMARCD2 (Gene) and SMARCD2 (Gene) is downregulated by Temsirolimus (Compound)
Exenatide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates CDK19 (Gene) and CDK19 (Gene) is upregulated by Temsirolimus (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Temsirolimus (Compound)
Exenatide may cause a minor interaction that can limit clinical effects when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Exenatide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin (Compound) downregulates TCEA2 (Gene) and TCEA2 (Gene) is upregulated by Temsirolimus (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)